BGI opens European research centre
BGI has opened its first European genome research centre, which is located in Copenhagen Bio Science Park (COBIS).
BGI has opened its first European genome research centre, which is located in Copenhagen Bio Science Park (COBIS). The centre is a collaboration between BGI and Danish research institutes, including the University of Copenhagen.
The centre plans to establish collaborations in Europe to develop genomics research and applications in healthcare, agriculture and bioenergy.
Ning Li, Director of BGI Europe, commented, “Our primary mission of this research centre is to provide BGI’s world-class expertise and infrastructure for the European researchers in genomics, proteomics, bioinformatics and other related areas. The opening of the genome research centre will add immense value on science advancement and application for both BGI Europe and Denmark.”
Thomas Bjørnholm, vice chancellor of the University of Copenhagen, said, “Both the facilities and the Danish and international scientists behind the centre are state-of-the-art. The vision is to create the best facilities in the fields of genomics and bioinformatics, so that we have an opportunity to use knowledge on genomics and better Denmark’s possibilities of preventing and curing diseases. For example, we hope that it will be possible to develop a vaccine for cancer.”
For more information please visit ref="http://www.genomics.cn">www.genomics.cn
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
